FDA clears AI tool to detect heart failure with low ejection fraction Dr. Kamal Kant Kohli8 April 2024 9:00 AM ISTThe US Food and Drug Administration (FDA) has cleared first AI tool to detect heart failure with low ejection fraction. Eko Low Ejection Fraction...
SGLT2 inhibitor ertugliflozin fails to prevent HF hospitalization at EF>60 percent: VERTIS CV analyses Medha Baranwal27 Oct 2023 12:30 PM ISTUSA: Post-hoc analyses of the VERTIS CV trial failed to show the ability of SGLT2 inhibitor ertugliflozin (Steglatro) to reduce hospitalization for...
High accuracy of bedside FoCUS EF evaluations supports heart failure diagnosis Medha Baranwal27 Sept 2023 8:00 PM ISTItaly: A recent study published in Internal and Emergency Medicine has revealed the high accuracy of the bedside focus cardiac ultrasound (FoCUS)...
Catheter ablation may significantly improve cardiac and renal function among AF patients with mid-range ejection fraction Aditi11 Aug 2023 8:00 PM ISTCatheter ablation as an effective treatment for atrial fibrillation (AF), and it is currently the first-line treatment for AF. The efficacy of...
Hemodynamic monitoring tied to improved QoL among heart failure patients: Monitor-HF Trial Dr. Kamal Kant Kohli14 July 2023 8:30 PM ISTA study published in the Lancet has concluded that those patients who were assigned to hemodynamic monitoring reported to have improved quality of...
AstraZeneca Forxiga approved in EU for treatment of symptomatic chronic heart failure Ruchika Sharma7 Feb 2023 4:15 PM ISTForxiga (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor.
Medical Bulletin 17/December/2022 Isra Zaman17 Dec 2022 2:15 PM ISTHere are the top medical news for the day:New, safer treatment for serious side effect of bone marrow transplant identifiedThe clinical trial in...
Patients with heart failure with improved ejection fraction benefit from the SGLT2 inhibitor dapagliflozin: Study Isra Zaman17 Dec 2022 10:00 AM ISTReduced ejection fraction heart failure develops when the left ventricle's muscle does not pump as well as it should. A 40% or lower ejection...
Empagliflozin improves outcomes in HF with preserved EF irrespective of BP: the EMPEROR-Preserved trial Medha Baranwal13 Dec 2022 10:30 AM ISTGermany: Empagliflozin reduces the risk of heart failure (HF) hospitalization or cardiovascular (CV) death in HRpEF (heart failure and preserved...
Torsemide does not confer any survival benefit over Furosemide in HF: TRANSFORM HF trial Dr.Niharika Harsha B7 Nov 2022 6:30 PM ISTResearchers have found in a new study that people treated with either loop diuretic medication furosemide or torsemide had similar death and...
Even lower doses of Sacubitril/valsartan suffice for improving outcomes in patients with HFrEF Jacinthlyn Sylvia12 Oct 2022 11:00 AM ISTAccording to a post hoc analysis of PROVE-HF, patients of heart failure who could not reach target dose of angiotensin receptor/neprilysin inhibitor...
Heart Failure with Preserved Ejection Fraction: Management Guidelines Dr. Nandita Mohan10 Aug 2022 9:00 AM ISTJournal of the Association of Physician of India (JAPI) reports a set of guidelines as Spironolactone and sacubitril-valsartan are beneficial in...
